参考文献/References:
[1] Eldemire R,Mestroni L,Taylor MRG. Genetics of dilated cardiomyopathy[J]. Annu Rev Med,2024,75:417-426.
[2] Arbelo E,Protonotarios A,Gimeno JR,et al. 2023 ESC Guidelines for the management of cardiomyopathies[J]. Eur Heart J, 2023,44(37):3503-3626.
[3] Helms AS,Thompson AD,Day SM. Translation of new and emerging therapies for genetic cardiomyopathies [J]. JACC Basic Transl Sci,2021,7(1):70-83.
[4] Heymans S,Lakdawala NK,Tsch?pe C,et al. Dilated cardiomyopathy:causes,mechanisms,and current and future treatment approaches[J]. Lancet,2023,402(10406):998-1011.
[5] Vidula MK,Bravo PE. Multimodality imaging for the diagnosis of infiltrative cardiomyopathies[J]. Heart,2022,108(2):98-104.
[6] Jordan E,Peterson L,Ai T,et al. Evidence-based assessment of genes in dilated cardiomyopathy[J]. Circulation,2021,144(1):7-19.
[7] Maron BJ,Desai MY,Nishimura RA, et al. Management of hypertrophic cardiomyopathy:JACC state-of-the-art review[J]. J Am Coll Cardiol,2022,79(4):390-414.
[8] Pua CJ,Tham N,Chin CWL,et al. Genetic studies of hypertrophic cardiomyopathy in Singaporeans identify variants in TNNI3 and TNNT2 that are common in Chinese patients[J]. Circ Genom Precis Med,2020,13(5):424-434.
[9] Rapezzi C,Aimo A,Barison A,et al. Restrictive cardiomyopathy:definition and diagnosis[J]. Eur Heart J,2022,43(45):4679-4693.
[10] Petersen SE,Jensen B,Aung N,et al. Excessive trabeculation of the left ventricle:JACC:cardiovascular imaging expert panel paper[J]. JACC Cardiovasc Imaging,2023,16(3):408-425.
[11] Oechslin E,Klaassen S. Left ventricular noncompaction:phenotype in an integrated model of cardiomyopathy?[J]. J Am Coll Cardiol,2019,73(13):1612-1615.
[12] Corrado D,Anastasakis A,Basso C,et al. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy:European Task Force consensus report[J]. Int J Cardiol,2024,395:131447.
[13] Alblaihed L,Kositz C,Brady WJ,et al. Diagnosis and management of arrhythmogenic right ventricular cardiomyopathy[J]. Am J Emerg Med,2023,65:146-153.
[14] Arbustini E,Narula N,Dec GW,et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy:endorsed by the World Heart Federation[J]. J Am Coll Cardiol,2013,62(22):2046-2072.
[15] Bishev D,Fabara S,Loseke I, et al. Efficacy and safety of mavacamten in the treatment of hypertrophic cardiomyopathy:a systematic review[J]. Heart Lung Cir c,2023,32(9):1049-1056.
[16] Argiro A,Bui Q,Hong KN,et al. Applications of gene therapy in?cardiomyopathies[J]. JACC Heart Fail,2024,12(2):248-260.
相似文献/References:
[1]占小锋 张长磊 李刚.β肾上腺素受体阻滞剂对甘油三酯代谢的影响及其作用机制的阐述[J].心血管病学进展,2019,(9):1298.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.029]
ZHAN Xiaofeng,ZHANG Changlei,LI Gang.Effect of -adrenergic Receptor Blockers on Triglyceride Metabolism and Mechanism[J].Advances in Cardiovascular Diseases,2019,(11):1298.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.029]
[2]王皎.室性期前收缩性心肌病诊疗进展[J].心血管病学进展,2020,(6):563.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.001]
WANG Jiao.Diagnosis and Treatment of Premature Ventricular Contraction-induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(11):563.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.001]
[3]谭莹 易龙 谢峻 徐标 陆剑嵘.一个家族肥厚心肌病的遗传学分析[J].心血管病学进展,2020,(8):880.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.023]
TAN Ying,YI Long,XIE Jun,et al.Genetic Analysis of A Familial Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(11):880.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.023]
[4]刘玉辉 王盼盼 陈椿.心房颤动性心肌病临床研究进展[J].心血管病学进展,2020,(12):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
LIU Yuhui,WANG Panpan,CHEN Chun.Atrial Fibrillation-induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(11):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
[5]王前程 刘伟涛 周忠江.提高对甲状腺素转运蛋白淀粉样变性心肌病诊治的认识[J].心血管病学进展,2021,(3):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
WANG Qiancheng,LIU Weitao,ZHOU Zhongjiang.To Improve the Recognition of Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
[6]陈秀 陈甘潇 张中和 胡丹 夏豪.钙通道突变致早期复极综合征的电生理机制研究[J].心血管病学进展,2021,(5):457.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.018]
CHEN Xiu,CHEN Ganxiao,ZHANG Zhonghe,et al.Electrophysiological Mechanism of Early Repolarization Syndrome Caused by Calcium Channel Mutation[J].Advances in Cardiovascular Diseases,2021,(11):457.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.018]
[7]杭成文 崔鸣.Myomesin基因家族及其相关疾病的研究进展[J].心血管病学进展,2021,(4):314.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.007]
HANG Chengwen,CUI Ming.Myomesin Gene Family and Related Diseases[J].Advances in Cardiovascular Diseases,2021,(11):314.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.007]
[8]徐尧 蔡衡 李洪仕.心房颤动合并心力衰竭的导管消融治疗[J].心血管病学进展,2021,(4):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
XU Yao,CAI Heng,LI Hongshi.Role of Radiofrequency Ablation in Patients with Atrial Fibrillation and Heart Failure[J].Advances in Cardiovascular Diseases,2021,(11):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
[9]刘珊珊,王岳恒,赵卉霖.肥厚心肌病动态梗阻的研究进展[J].心血管病学进展,2021,(6):508.[doi:10.16806/j.cnki.issn.1004-3934.20.06.008]
LIU Shanshan,WANG Yueheng,ZHAO Huilin.Dynamic Obstruction in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):508.[doi:10.16806/j.cnki.issn.1004-3934.20.06.008]
[10]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]